PROs Support Switching to Camizestrant Plus CDK4/6 Inhibitor for HR-positive, HER2-negative ABC and Emergent ESR1 Mutations During First-Line Endocrine-Based Therapy By Ogkologos - November 10, 2025 197 0 Facebook Twitter Google+ Pinterest WhatsApp Patient-reported outcomes from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Omission of Surgical Axillary Staging Noninferior To Sentinel Lymph Node Biopsy... January 14, 2025 Visits to Online Breast Cancer Communities Could Help Policy Makers and... February 11, 2021 Efficacy of Taletrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC April 18, 2025 EMA Recommends Extension of Indications for Durvalumab to Include Treatment of... March 28, 2025 Load more HOT NEWS Proton and Intensity-Modulated Radiation Therapy for Oropharyngeal Cancer Show Similar Late Effects, QoL,... ¿Las gammagrafías óseas muestran el cáncer? Dr. Alan S. Rabson, Long-Time NCI Deputy Director and Cancer Research... The Caregiver Curve
